# A Study to Evaluate the Safety and Tolerability of BMS-986403 in Participants With Relapsed and/or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

> **NCT05244070** · PHASE1 · TERMINATED · sponsor: **Bristol-Myers Squibb** · enrollment: 5 (actual)

## Conditions studied

- Leukemia, Lymphocytic, Chronic, B-Cell
- Lymphoma

## Interventions

- **DRUG:** BMS-986403
- **DRUG:** Fludarabine
- **DRUG:** Cyclophosphamide

## Key facts

- **NCT ID:** NCT05244070
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-09-14
- **Primary completion:** 2023-05-04
- **Final completion:** 2023-05-04
- **Target enrollment:** 5 (ACTUAL)
- **Why stopped:** Business objectives have changed.
- **Last updated:** 2023-07-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05244070

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05244070, "A Study to Evaluate the Safety and Tolerability of BMS-986403 in Participants With Relapsed and/or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT05244070. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*